Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

Health Pharma & Biotech Written by: Angela Harmantas 10:32 Sat 12 Sep 2026 --> Proactive has a commercial relationship with Medicus Pharma. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. She earned a Bachelor of... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Medicus Pharma ( NASDAQ:MDCX ) View Price & Profile Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI Published: 10:32 12 Sep 2026 EDT Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. Bokhari said final SkinJect results published on ClinicalTrials.gov had confirmed the 200-microgram patch as the dose to be taken forward into further registrational studies. He said Medicus Pharma (NASDAQ:MDCX) would continue focusing on Gorlin syndrome, including steps to recruit patients for the SkinJect 005 study and work towards the pivotal study that he said had already received FDA approval. Meanwhile, the nodular basal cell carcinoma opportunity has been positioned for an out-licence. “We are very excited that we have clarity on our way forward,” Bokhari said, adding that the prospect of SkinJect becoming a therapy for Gorlin syndrome patients with multiple basal cell lesions was getting “closer and closer”. A potential partnership represents another catalyst. Bokhari described the program as “clearly partner-ready” and said Medicus Pharma hoped a partner could take the baton while the company continued development work. He also pointed to the potential commercial characteristics of the rare disease opportunity. An independent report commissioned by Medicus Pharma indicated potential reimbursement of around $25,000 or more, according to Bokhari. Alongside SkinJect, the company is advancing a co-development and licensing opportunity with Pfizer involving a CD228-targeted antibody-drug conjugate to explore its efficacy in refractory melanoma and other solid tumours. Bokhari said the Pfizer relationship came with $2 million in development funding as well as inventory and infrastructure support. He said Medicus Pharma was therefore adequately funded, and potentially fully funded, to pick up where Pfizer left off with a Phase 1 dose-escalation study. He described the addition of the program as a “paradigm shift” in the company’s portfolio, providing an opportunity for Medicus Pharma to refine its position as a precision oncology-led biotech life sciences company. For investors, potential catalysts highlighted in the interview include progress towards recruitment for SkinJect 005, advancement of the pivotal Gorlin syndrome program, a potential SkinJect partnership and further development of the CD228-targeted antibody-drug conjugate program. Continue reading